Source: ClinicalTrials.gov — U.S. National Library of Medicine — A database of privately and publicly funded clinical studies conducted around the world (U.S. National Library of Medicine, public domain).
This page lists clinical trials related to Skin Infections from the ClinicalTrials.gov database.
Trial Summary
- Total studies: 50
- Recruiting: 25
- Active, not recruiting: 8
- Completed: 7
- Other: 10
Results are refreshed periodically and may not reflect the most current information available from ClinicalTrials.gov.
Recruiting Trials
NCT00001230 — Host Response to Infection and Treatment in Filarial Diseases
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 500 |
| Study Type | OBSERVATIONAL |
| Conditions | Filariasis; Helminthiasis; Parasitic Infection; Mansonelliasis; Onchocerciasis |
| Interventions |
This study will evaluate and treat patients with filarial infections to explore in depth the immunology of the disease, including susceptibility to infection, disease development, and response to treatment. Filarial infections are caused by parasitic worms. The immature worm (larva) is transmitted to a person through a mosquito bite and grows in the human body to 2 to 4 inches in length. Althou…
NCT00344188 — Diagnosis and Treatment of Leishmania Infections
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 289 |
| Study Type | OBSERVATIONAL |
| Conditions | Leishmaniasis; Skin Diseases, Parasitic; Euglenozoa Infections; Parasitic Diseases |
This study will examine the natural history of Leishmanial infections and their treatments. It will provide an opportunity for NIAID staff to learn more about leishmaniasis and perhaps to improve diagnostic tests for these infections. Patients between 2 and 80 years of age with known or suspected leishmaniasis are eligible for this study.
Participants will have routine blood tests and a biopsy…
NCT00032513 — Genetic Studies of Chronic Active Epstein-Barr Disease
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 300 |
| Study Type | OBSERVATIONAL |
| Conditions | Chronic Active Epstein-Barr Virus |
Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes infectious mononucleosis. It has also been associated with certain forms of cancer. Chronic Epstein-Barr virus (CAEBV) is a rare disease, primarily of children and you…
NCT02193295 — Reversal of Lipid-Induced Insulin Resistance
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Yale University |
| Enrollment | 250 |
| Study Type | INTERVENTIONAL |
| Conditions | Insulin Resistance; NAFLD |
| Interventions |
The purpose of this study is to examine whether weight reduction decreases intramyocellular (IMCL) and hepatic lipid content, and improves insulin sensitivity of muscle and fat tissue in people who are insulin resistant and have a family history of type 2 diabetes.
Hepatic mitochondrial oxidation will be assesses using a 3 hour triple tracer study (D7 glucose, 3-13C lactate and 13C4 beta-hydro…
NCT01011712 — The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 600 |
| Study Type | OBSERVATIONAL |
| Conditions | EBV; HSV; VZV; HPV; CMV |
Background:
- Infections caused by viruses are common causes of illnesses: the common cold, many ear infections, sore throats, chicken pox, and the flu are caused by different viruses. Usually, these illnesses last only few days or, at most, a few weeks. Some virus infections like influenza are cleared from the body, and others such as the chicken pox virus remain in the body in an inactive st…
NCT00967785 — A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 20 |
| Study Type | INTERVENTIONAL |
| Conditions | Leukopenia; Neutropenia; Infections; Warts; Myelokathexis |
| Interventions |
Background:
- WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is caused by various genetic changes that increase the activity of the chemokine receptor, CXCR4. Excessive function of this receptor causes mature neutrophils (part of the white blood cells) to be retained within the bone marrow rather than being released to the blood and is one of the causes of severe …
NCT01306084 — Viral Infections in Healthy and Immunocompromised Hosts
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 1000 |
| Study Type | OBSERVATIONAL |
| Conditions | Anogenital Herpes; COVID-19; Herpes Labialis |
Background:
- Viral infections are an important cause of illness and death in hospitalized patients as well as outpatients. New strains of viruses may appear and infect both healthy people and those with weak immune systems. A better understanding of these new virus strains (such as SARS-CoV-2, the virus that causes COVID-19) may help to control and prevent these infections. In particular, so…
NCT01905826 — Natural History Study of GATA2 Deficiency and Related Disorders
| Status | Recruiting |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 600 |
| Study Type | OBSERVATIONAL |
| Conditions | GATA2 Deficiency |
Background:
- GATA2 deficiency is a genetic disorder that can cause problems with a person s immune system and other body systems. Some people who have this disorder develop few problems from it. Others can have a wide range of health problems, from skin problems, to hearing loss, to cancer. These problems can happen at any age. Researchers want to study GATA2 deficiency to better understand …
NCT04344119 — Assessment of Chilbains Occuring During Covid-19 Infection
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Enrollment | 30 |
| Study Type | OBSERVATIONAL |
| Conditions | Skin Manifestations; COVID; Chilblains |
Some patients infected by covid-19 develop skin manifestations. These manifestations are still not well known and there pathophysiology remain unclear. Among them, acral manifestation resembling to chilblains appears frequent and quite specific. The aim of this project is to better characterize the cutaneous manifestations occurring during Covid-19 infection with a special focus on chilblains. …
NCT04975152 — Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Enrollment | 36 |
| Study Type | INTERVENTIONAL |
| Conditions | Merkel Cell Carcinoma; Cutaneous Squamous Cell Carcinoma |
| Interventions |
The goal of this clinical research study is to determine if Cemiplimab-rwlc (called Cemiplimab in this document) given prior to tumor resection surgery is safe and effective in treating (1) Merkel Cell Carcinoma or (2) Cutaneous Squamous Cell Carcinoma (CSCC).
NCT05269381 — Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | Mayo Clinic |
| Enrollment | 132 |
| Study Type | INTERVENTIONAL |
| Conditions | Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IIIA Breast Cancer AJCC v8; Anatomic Stage IIIB Breast Cancer AJCC v8; Anatomic Stage IIIC Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 |
| Interventions | ; ; |
This phase I/II trial tests the safety and tolerability of an experimental personalized vaccine when given by itself and with pembrolizumab in treating patients with solid tumor cancers that have spread to other places in the body (advanced). The experimental vaccine is designed target certain proteins (neoantigens) on individuals’ tumor cells. Immunotherapy with monoclonal antibodies, such as …
NCT06481163 — Telacebec (T) Treatment in Adults With Buruli Ulcer (BU). (TREAT BU)
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Barwon Health |
| Enrollment | 200 |
| Study Type | INTERVENTIONAL |
| Conditions | Buruli Ulcer |
| Interventions |
The goal of this interventional clinical trial is to demonstrate the complete BU lesion healing rate by 52 weeks after treatment initiation, without relapse and/or curative intent excision surgery, after 10-28 days of telacebec (T) treatment. Males and females age 18 and older will be included.
• Participants will attend visits every 2 weeks during treatment and thereafter every 2 weeks until …
NCT07659769 — Global Healthcare Study on Hidradenitis Suppurativa
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Julia Tatjana Maul |
| Enrollment | 9600 |
| Study Type | OBSERVATIONAL |
| Conditions | Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa) |
The Global Healthcare Study on Hidradenitis Suppurativa (GHSHS) is an international, multicenter observational study hosted by the University of Zurich (UZH) investigating healthcare access, treatment patterns, disease severity, and quality of life in patients with psoriasis. The study collects standardized clinical data from routine medical records to identify disparities in healthcare deliver…
NCT06855498 — Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Incyte Corporation |
| Enrollment | 600 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa (HS) |
| Interventions |
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
NCT06921850 — A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | UCB Biopharma SRL |
| Enrollment | 40 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions |
The purpose of the study is to assess the PK of bimekizumab following subcutaneous (sc) administration in study participants with moderate to severe hidradenitis suppurativa (HS)
NCT07115043 — A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
| Status | Recruiting |
| Phase | Phase 1 / Phase 2 |
| Sponsor | AstraZeneca |
| Enrollment | 60 |
| Study Type | INTERVENTIONAL |
| Conditions | Melanoma; Non-small Cell Lung Cancer; Squamous Cell Carcinoma (Skin); Renal Cell Carcinoma; Merkel Cell Carcinoma |
| Interventions | ; |
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
NCT07049575 — Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Incyte Corporation |
| Enrollment | 24 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions |
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 142 |
| Study Type | OBSERVATIONAL |
| Conditions | Hidradenitis Suppurativa |
The HS-RISE study aims to assess real-world HS treatment outcomes and patterns, safety of secukinumab, and to describe the baseline characteristics of patients diagnosed with moderate-to- severe HS who are prescribed secukinumab in Canadian routine clinical practice.
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Sanofi |
| Enrollment | 144 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions | ; |
This is a multinational, randomized, double-blind, placebo-controlled, Phase 2, dose finding study to evaluate the efficacy and safety of different doses of SAR445399 in adult participants with moderate to severe hidradenitis suppurativa.
The purpose of this study is to assess the efficacy and safety of two doses of SAR445399 compared with placebo in adult participants with moderate to severe …
NCT07000110 — Anifrolumab Malignancy and Serious Infections Study
| Status | Recruiting |
| Phase | N/A |
| Sponsor | AstraZeneca |
| Enrollment | 3195 |
| Study Type | OBSERVATIONAL |
| Conditions | Systemic Lupus Erythematosus |
| Interventions |
This is an observational study, in which the main research question is to evaluate the risk of malignancies and serious infections among moderate/severe SLE patients who receive anifrolumab compared with a comparable population of moderate/severe SLE patients on standard of care who do not initiate anifrolumab.
NCT07213973 — Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Incyte Corporation |
| Enrollment | 40 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa (HS) |
| Interventions |
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of povorcitinib in adolescent participants with moderate to severe hidradenitis suppurativa over a 54-week open-label treatment period.
NCT07660354 — Safety, Efficacy and Preventative Effect of a Head Lice Product (X92001483) vs. Nix Creme Rinse (1% Permethrin).
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Oystershell NV |
| Enrollment | 98 |
| Study Type | INTERVENTIONAL |
| Conditions | Lice; Head Lice |
| Interventions |
To compare the safety, effectiveness, and preventive benefits of a medical device (X92001483) against Nix Cream Rinse (1% Permethrin) in people with head lice
NCT07387198 — Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
| Enrollment | 135 |
| Study Type | INTERVENTIONAL |
| Conditions | Merkel Cell Carcinoma, Stage I; Merkel Cell Carcinoma, Stage II; Neoadjuvant Immunotherapy |
| Interventions | ; |
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
NCT07686913 — Steri-Strip Application Versus Standard Wound Closure for Cesarean Section Incisions
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Riverside University Health System Medical Center |
| Enrollment | 610 |
| Study Type | INTERVENTIONAL |
| Conditions | Cesarean Section; Surgical Site Infection; Wound Dehiscence; Seroma |
| Interventions | ; |
This study is evaluating whether Steri-Strips® provide additional benefits when used after cesarean section (C-section) surgery. Steri-Strips are adhesive strips that are commonly placed over a surgical incision to provide support while the wound heals. At our hospital, Steri-Strips are routinely used after C-sections in addition to standard wound closure techniques, although they are not consi…
NCT07524062 — The Application of Infrared Thermography in the Prediction of Skin Healing in Surgery
| Status | Recruiting |
| Phase | N/A |
| Sponsor | Universitaire Ziekenhuizen KU Leuven |
| Enrollment | 120 |
| Study Type | INTERVENTIONAL |
| Conditions | Wound Healing; Surgical Wound Infection; Postoperative Complications; Skin Neoplasms; Skin Transplantation |
| Interventions |
This study investigates whether infrared thermography, a harmless and non-invasive thermal camera technique, can help monitor how surgical wounds heal after skin surgery. The goal is to detect wound problems earlier, such as infection or delayed healing, and to support doctors in making timely clinical decisions.
Active, Not Recruiting
NCT04901195 — A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Sponsor | UCB Biopharma SRL |
| Enrollment | 658 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions |
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
NCT05632601 — Reexamining Her Cardiovascular Risk - Ottawa WomeN’s Longitudinal Cohort Study
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | Ottawa Heart Institute Research Corporation |
| Enrollment | 176 |
| Study Type | INTERVENTIONAL |
| Conditions | Cardiovascular Diseases |
| Interventions |
The full HER CROWN will be a prospective cohort study to propose a novel, women-specific cardiovascular risk score/ algorithm in the prediction of hard cardiovascular outcomes (myocardial infarction, unstable angina, coronary revascularization, stroke, total and cardiovascular mortality). This future study will be the first longitudinal cohort study, to our knowledge, that is focused entirely o…
NCT06002685 — Partners in Children’s Health (CSN): A Randomized Trial of an Attachment Based Intervention
| Status | Active, not recruiting |
| Phase | N/A |
| Sponsor | University of Maryland, Baltimore |
| Enrollment | 260 |
| Study Type | INTERVENTIONAL |
| Conditions | Respiratory Disease; Inflammation; Insufficient Sleep; Digestive Disease; Skin Conditions |
| Interventions | ; |
The goal of this randomized controlled trial is to evaluate the impacts of an attachment-based intervention (Attachment Biobehavioral Catch-Up (ABC) and Home Book-of-the-Week (HBOW) program on emerging health outcomes (i.e., common childhood illnesses, body mass index, and sleep) in low-income Latino children (N=260; 9 months at enrollment). It is hypothesized that children randomized to ABC wi…
NCT06046729 — A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 352 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions | ; |
This study aims to find the appropriately safe and effective dose and dosing frequency for eltrekibart in adults with moderate-to-severe hidradenitis suppurativa (HS) for further clinical development. The study will last approximately 62 weeks and may include up to 31 visits.
NCT05947500 — Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | National Cancer Institute (NCI) |
| Enrollment | 50 |
| Study Type | INTERVENTIONAL |
| Conditions | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Locally Advanced Merkel Cell Carcinoma; Metastatic Merkel Cell Carcinoma; Refractory Merkel Cell Carcinoma |
| Interventions | ; ; |
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, w…
NCT06468228 — A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Sponsor | AbbVie |
| Enrollment | 1400 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions | ; |
Hidradenitis suppurativa (HS) is a chronic and often painful inflammatory skin disease which includes the forming of lumps, abscesses and scars in areas of the skin such as under the breasts, under armpits, inner thighs, groin and buttocks. This study will compare lutikizumab versus placebo for the treatment of adult and adolescent participants with the signs and symptoms of moderate to severe …
NCT06993610 — Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
| Status | Active, not recruiting |
| Phase | Phase 2 |
| Sponsor | Zura Bio Inc |
| Enrollment | 225 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa (HS) |
| Interventions | ; ; |
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 16 weeks (Period 1) in adults with hidradenitis suppurativa, followed by a 16-week open-label extension period in which all participants will receive tibulizumab (Period 2)
NCT06958211 — Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
| Status | Active, not recruiting |
| Phase | Phase 3 |
| Sponsor | Incyte Corporation |
| Enrollment | 573 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions | ; |
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
Not Yet Recruiting
NCT07668713 — FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | University Hospital, Clermont-Ferrand |
| Enrollment | 24 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa (HS); Fecal Microbiota Transplantation (FMT) |
| Interventions |
The medical and surgical treatment of hidradenitis suppurativa (HS) remains difficult to date. The search for new therapies for HS is a major challenge. The pathophysiology of HS, the similarities with Crohn’s disease and the data in the literature suggest a role for the digestive flora in HS. The role of the intestinal microbiota has now been clearly demonstrated in the pathophysiology of chro…
NCT07668999 — A Phase 1b Study of ZYG24004 in Participants With Tinea Pedis Caused by Dermatophytes
| Status | Not yet recruiting |
| Phase | Phase 1 |
| Sponsor | Sinomune Pharmaceutical Co., Ltd |
| Enrollment | 64 |
| Study Type | INTERVENTIONAL |
| Conditions | Tinea Pedis |
| Interventions | ; ; |
This is a multicenter, randomized, double-blind, placebo-controlled Phase 1b study in adult participants with tinea pedis caused by dermatophytes. The study will evaluate the safety, local tolerability, and pharmacokinetic profile of two concentrations of ZYG24004 (1% and 3%) after topical administration once or twice (once weekly for two consecutive weeks), and will explore preliminary efficacy.
NCT07665437 — An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 710 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions |
The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.
NCT07240649 — Emerging Indications for Hyperbaric Oxygen Treatment
| Status | Not yet recruiting |
| Phase | Phase 4 |
| Sponsor | Jay C. Buckey Jr. |
| Enrollment | 100 |
| Study Type | INTERVENTIONAL |
| Conditions | Post-COVID-19 Condition; Ulcerative Colitis; Crohn Disease; Calciphylaxis; Frostbite |
| Interventions | ; |
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric Oxygen Treatment. The study team aims to collect ongoing data on how well HBOT treats these emerging indications, and to add these data to the growing HBO Registry. The re…
NCT07689188 — Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
| Status | Not yet recruiting |
| Phase | Phase 2 |
| Sponsor | Harrison Dermatology |
| Enrollment | 10 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa (HS) |
| Interventions |
This study investigates the efficacy of topical roflumilast foam in patients with HS.
NCT07665476 — Naproxen Versus Placebo as Adjunct Treatment of Cellulitis
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Ottawa Hospital Research Institute |
| Enrollment | 884 |
| Study Type | INTERVENTIONAL |
| Conditions | Cellulitis; Skin Disease, Infectious; Infection; Skin and Soft Tissue Infections (SSTIs) |
| Interventions | ; ; |
Cellulitis is a painful bacterial skin infection commonly seen in Canadian emergency departments. Cellulitis has a negative impact on patients’ quality of life and productivity. While this is a bacterial infection, there is evidence inflammation also contributes to the disabling symptoms of pain, redness and swelling. Some studies have suggested that a nonsteroidal anti-inflammatory drug (NSAID…
NCT07675239 — Comparison of Itraconazole With Itraconazole and Isotretinoin in the Treatment Duration, Safety a n d Cure Rate in Adult Patients of Tinea Corporis/ Cruris-A Randomised Controlled Trail
| Status | Not yet recruiting |
| Phase | Phase 4 |
| Sponsor | Pak Emirates Military Hospital |
| Enrollment | 60 |
| Study Type | INTERVENTIONAL |
| Conditions | Tinea Corporis |
| Interventions | ; |
Tinea corporis and tinea cruris are common superficial fungal infections that have become increasingly difficult to treat because of prolonged disease duration, frequent recurrences, and suboptimal response to standard antifungal therapy. Itraconazole is widely used for the treatment of dermatophytosis; however, treatment failures and relapses remain a significant concern. Isotretinoin has been…
NCT07690319 — A Study of Early Secukinumab Treatment in Moderate to Severe Hidradenitis Suppurativa Patients
| Status | Not yet recruiting |
| Phase | N/A |
| Sponsor | Novartis Pharmaceuticals |
| Enrollment | 186 |
| Study Type | OBSERVATIONAL |
| Conditions | Hidradenitis Suppurativa |
The aim of this study is to evaluate the effectiveness of early treatment with secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) and assess its impact on disease progression using data from multiple European data sources. All data will be sourced from existing non-interventional study primary data collection, registries, and hospital cohorts that captured information…
Completed Trials
NCT00353158 — A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
| Status | Completed |
| Phase | Phase 1 |
| Sponsor | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| Enrollment | 62 |
| Study Type | INTERVENTIONAL |
| Conditions | Healthy Volunteers; Fungal Infections; Bacterial Infections |
| Interventions | ; |
This study will examine the phototoxicity, a reaction to light that is like exaggerated sunburn, which occurs in people who take medications such as voriconazole, a medication used to fight fungus. Sunscreens might protect the skin from the reaction. Although phototoxicity from voriconazole is not completely understood, it may be related to how that medication is metabolized in the liver by enz…
NCT02231879 — Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
| Status | Completed |
| Phase | Phase 2 / Phase 3 |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 20 |
| Study Type | INTERVENTIONAL |
| Conditions | Myelokathexis; Infections; Neutropenia; Warts; Hypogammaglobulinemia |
| Interventions | ; |
Background:
- WHIMS (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome) is a rare disease. It can cause cancers, infections, and warts. Researchers want to see if a drug called plerixafor can treat WHIMS.
Objective:
- To compare plerixafor versus granulocyte colony stimulating factor (G-CSF) for preventing infections in people with WHIMS.
Eligibility:
- People ages 10…
NCT04926922 — PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
| Status | Completed |
| Phase | N/A |
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Enrollment | 200 |
| Study Type | OBSERVATIONAL |
| Conditions | Tuberculosis; HIV |
Background:
Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster. TB is a leading cause of death among people in the West African country of Liberia. Researchers want to find an effective testing method for latent tuberculosis infection (LTBI) t…
NCT05764876 — Repurposing Clinically Approved Drugs for Yaws With an Insight Into the Cutaneous Ulcer Disease Syndrome (Trep-AByaws)
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia |
| Enrollment | 384 |
| Study Type | INTERVENTIONAL |
| Conditions | Yaws; Cutaneous Ulcer |
| Interventions | ; |
The goal of this clinical trial is to test the non inferiority of linezolid compared with azithromycin as a treatment for yaws . The main questions it aims to answer are: can linezolid cure active yaws, and can linezolid cure latent yaws. Participants with serologically confirmed yaws will be randomized to receive linezolid (experimental) or azithromycin (control group) treatment and followed u…
NCT06175013 — Evaluation of a Combination of Two Medical Devices and One Device Use in the Treatment of Toenail Onychomycosis
| Status | Completed |
| Phase | N/A |
| Sponsor | Swiss Footcare Laboratories - Poderm Professional |
| Enrollment | 44 |
| Study Type | INTERVENTIONAL |
| Conditions | Onychomycosis |
| Interventions | ; |
The goal of this clinical investigation is to evaluate the efficacy of the tested products in medium to moderate onychomycosis after 112 days of treatments.
The main question it aims to answer is the effectiveness of the use of a combination of two investigational devices (Sérum PURIFIANT + Sérum BOOSTER) on the percentage of healthy nail surface after 112 days of treatment.
Participants will…
NCT07338773 — Intraosseous Versus Intravenous Vancomycin in Below-Knee Amputation for Ischemic Diabetic Foot
| Status | Completed |
| Phase | Phase 4 |
| Sponsor | Başakşehir Çam & Sakura City Hospital |
| Enrollment | 40 |
| Study Type | INTERVENTIONAL |
| Conditions | Diabetic Foot Disease; Diabetic Foot Infection; Diabetic Amputation Foot Wound |
| Interventions | ; |
This randomized clinical trial compared two routes of vancomycin administration in patients undergoing below-knee amputation for ischemic diabetic foot infection. Patients with diabetic foot infection and impaired lower-extremity circulation may have reduced delivery of intravenously administered antibiotics to the amputation stump. Intraosseous administration may increase local antibiotic expo…
NCT07673484 — Tattooing and Piercing Among Medical Students
| Status | Completed |
| Phase | N/A |
| Sponsor | Biruni University |
| Enrollment | 180 |
| Study Type | OBSERVATIONAL |
| Conditions | Keloid; Tattoo; Infection; Scar; Allergic Contact Dermatitis |
The aim of this study is to evaluate medical students’ attitudes towards tattoos and piercings and to measure their awareness of associated dermatological risks.
Other (Terminated)
NCT04067219 — SkIn, Muscle and Bone Aging Determinants in HIV Infected-patients.
| Status | Terminated |
| Phase | N/A |
| Sponsor | University Hospital, Bordeaux |
| Enrollment | 123 |
| Study Type | INTERVENTIONAL |
| Conditions | HIV-1-infection; Marker; Structural |
| Interventions |
this study consists of the study of markers of skin, muscular, neurocognitive and bone aging in HIV infected adults and to compare the frequency of these signs to the general population of same gender and age.
NCT06685835 — A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)
| Status | Terminated |
| Phase | Phase 2 |
| Sponsor | Insmed Incorporated |
| Enrollment | 214 |
| Study Type | INTERVENTIONAL |
| Conditions | Hidradenitis Suppurativa |
| Interventions | ; |
The primary purpose of the study is to evaluate the effect of brensocatib compared with placebo.